Last updated: August 31, 2026
Darifenacin hydrobromide is a mature, genericized overactive bladder drug marketed originally as Enablex in the United States. Its commercial profile has shifted from branded specialty revenue to low-cost generic volume. The principal market constraints are therapeutic substitution, competition from newer branded agents, limited differentiation for the extended-release formulation, and the absence of meaningful remaining exclusivity.
What is darifenacin hydrobromide used for?
Darifenacin hydrobromide is an orally administered, once-daily, extended-release muscarinic M3 receptor antagonist for the treatment of overactive bladder. The FDA indication covers urge urinary incontinence, urgency, and urinary frequency in adults.[1]
The drug reduces bladder detrusor muscle activity through relative selectivity for the M3 receptor. The commercial product is supplied as extended-release tablets, typically in 7.5 mg and 15 mg strengths.
| Attribute |
Darifenacin hydrobromide |
| Original U.S. brand |
Enablex |
| Active ingredient |
Darifenacin hydrobromide |
| Drug class |
Antimuscarinic |
| Primary indication |
Overactive bladder |
| Dosage form |
Extended-release oral tablet |
| Common strengths |
7.5 mg and 15 mg |
| Original innovator |
Novartis |
| U.S. NDA |
021513 |
| FDA approval |
2004 |
| Current commercial status |
Genericized, mature market |
Darifenacin is differentiated pharmacologically by M3 receptor selectivity, but this distinction has not produced durable commercial insulation. Physicians and payers generally evaluate it against other oral antimuscarinics and beta-3 adrenergic agonists.
When did darifenacin lose exclusivity?
Darifenacin lost meaningful U.S. commercial exclusivity after generic entry. The branded product no longer controls the category, and multiple generic manufacturers have supplied or sought approval for darifenacin extended-release tablets.
The principal loss-of-exclusivity drivers were:
- Expiration or exhaustion of the core composition and formulation patent estate.
- Generic approvals covering the same extended-release dosage form.
- Declining prescriber reliance on the Enablex brand.
- Payer substitution toward lower-cost antimuscarinics and alternative drug classes.
The FDA’s Orange Book identifies the approved reference product and associated patent and exclusivity information. Generic applicants may rely on the Enablex NDA through an abbreviated new drug application under Section 505(j) of the Federal Food, Drug, and Cosmetic Act.[2]
Darifenacin exclusivity timeline
| Period |
Commercial or regulatory event |
| 1990s |
Darifenacin development and patent filings |
| 2004 |
FDA approval of Enablex for overactive bladder |
| Late 2000s |
Brand commercialization and expansion of payer coverage |
| Early 2010s |
Generic-development activity and patent-expiration pressure |
| 2011-2013 |
Broad generic market entry period |
| 2013 onward |
Product transition from branded revenue to generic volume |
| 2020s |
Mature, price-competitive generic market |
Exact generic launch timing varied by manufacturer and dosage strength. The key financial event was the transition from a single branded supplier to multiple abbreviated new drug application holders.
What patents protect darifenacin hydrobromide?
The historical patent estate covered the darifenacin molecule, pharmaceutical salts, formulations, and controlled-release delivery characteristics. The most commercially relevant protection involved the active compound and extended-release oral dosage form.
A commonly cited U.S. patent associated with Enablex is U.S. Patent No. 6,656,957. The patent family relates to quinuclidine derivatives and includes darifenacin-related subject matter. Patent-term calculations depend on priority claims, terminal disclaimers, patent-term adjustment, patent-term extension, and the specific claim scope.[3]
| Protection category |
Relevance to darifenacin |
| Active compound patents |
Protected the chemical entity and related derivatives |
| Salt patents |
Covered pharmaceutically acceptable salts, including hydrobromide |
| Formulation patents |
Addressed extended-release oral delivery |
| Method-of-use patents |
Covered treatment of urinary urgency, frequency, and urge incontinence |
| Manufacturing patents |
May have covered synthesis, purification, or crystalline forms |
The remaining commercial value of these patents is limited because generic products are already established. Any surviving formulation or manufacturing claims would need to be evaluated against the specific generic product, its process, and the patent’s enforceability.
What is the Orange Book status of Enablex and darifenacin?
Enablex is the reference listed drug for darifenacin extended-release tablets in the United States. The FDA Orange Book records the reference product, approved strengths, patent listings, and generic equivalents.[2]
The relevant regulatory structure is:
- NDA 021513 for Enablex.
- Generic ANDAs for darifenacin hydrobromide extended-release tablets.
- Reference strengths generally corresponding to 7.5 mg and 15 mg.
- Orange Book patent listings that historically supported brand exclusivity and generic certification analysis.
The Orange Book does not establish that a listed patent is valid or infringed. It records the sponsor’s patent certifications and FDA listing information. Patent disputes require separate analysis of the asserted claims, ANDA notice letters, district court filings, and any settlement terms.
Which companies challenged or entered the darifenacin market?
Generic entry came from manufacturers active in the oral solid-dose market. Publicly identified suppliers have included companies such as Actavis, Apotex, Glenmark, and other ANDA sponsors, depending on the market period and product availability.
The competitive structure is fragmented:
| Segment |
Typical participants |
Competitive basis |
| Original brand |
Novartis; later commercial partners |
Brand recognition, formulary access |
| Generic oral tablets |
Multiple ANDA holders |
Price, supply reliability, wholesaler access |
| Branded alternatives |
Astellas, Pfizer, Viatris, other firms |
Differentiated mechanisms, marketing, dosing |
| Low-cost legacy drugs |
Oxybutynin, tolterodine, trospium |
Broad generic availability and low price |
A complete list of current manufacturers requires a current FDA product-file review because approvals, discontinuations, and labeler ownership change over time.
How does darifenacin compare with competing overactive bladder drugs?
Darifenacin competes in a crowded market with both antimuscarinics and beta-3 adrenergic agonists.
| Drug |
Class |
Commercial position |
Main competitive issue |
| Darifenacin |
M3-selective antimuscarinic |
Generic |
Anticholinergic tolerability and low price |
| Solifenacin |
Antimuscarinic |
Generic and historically branded |
Stronger prescribing familiarity |
| Tolterodine |
Antimuscarinic |
Generic |
Established use and price |
| Oxybutynin |
Antimuscarinic |
Generic |
Very low cost but tolerability concerns |
| Trospium |
Antimuscarinic |
Generic |
Alternative pharmacokinetic profile |
| Fesoterodine |
Antimuscarinic |
Branded/generic depending market |
Extended-release positioning |
| Mirabegron |
Beta-3 agonist |
Branded and increasingly generic in some markets |
Avoids some anticholinergic effects but has price and safety considerations |
| Vibegron |
Beta-3 agonist |
Branded |
Newer mechanism and commercial differentiation |
Darifenacin’s M3 selectivity can support a clinical positioning argument, particularly for patients in whom bladder selectivity is desirable. That benefit has not created a durable pricing premium after generic entry. Clinical guidelines and comparative reviews treat antimuscarinics as a broad class, with drug selection influenced by efficacy, dry-mouth and constipation risk, cognitive concerns, cardiovascular considerations, renal and hepatic factors, and formulary restrictions.[4]
What formulation patents protect darifenacin?
The commercially important formulation is an extended-release tablet designed for once-daily administration. Formulation protection historically addressed release control, tablet composition, and pharmacokinetic delivery.
The formulation has limited present-day strategic value for three reasons:
- The dosage form is an established oral solid-dose platform.
- Generic manufacturers have demonstrated technical capability to reproduce the release profile.
- The market does not appear to support a high-priced reformulation absent a meaningful clinical advantage.
Potentially valuable formulation strategies would include a genuinely differentiated delivery system, such as a lower-burden dosing schedule, improved gastrointestinal tolerability, or a route that avoids first-pass metabolism. No such major commercial reformulation has displaced the standard extended-release tablet.
What method-of-use patents cover darifenacin?
Historical method-of-use claims covered treatment of overactive bladder symptoms, including urinary urgency, frequency, and urge urinary incontinence. Method-of-use patents can create a narrower barrier than composition patents because generic applicants may use Section viii labeling strategies to omit patented indications where permitted.
For darifenacin, the central commercial indication is already well established and genericized. A method-of-use patent would have limited practical value unless it covered a high-value patient segment, a novel combination, or a materially differentiated clinical outcome.
Potential method-of-use areas include:
- Treatment of urge urinary incontinence.
- Management of urinary frequency and urgency.
- Use in selected patients with particular comorbidities.
- Combination treatment with other overactive bladder therapies.
- Mitigation of adverse effects through dose selection or administration timing.
No major late-stage method-of-use franchise is publicly associated with darifenacin comparable to the lifecycle-management programs used for newer branded therapies.
What is the financial trajectory of darifenacin?
Darifenacin followed the standard small-molecule loss-of-exclusivity pattern:
- Initial branded growth after FDA approval.
- Commercial support through specialist and primary-care prescribing.
- Revenue pressure from competing antimuscarinics.
- Steep brand erosion after generic approval.
- Conversion from product-level brand revenue to low-margin generic sales.
Standalone current revenue is not publicly reported for darifenacin because the product is distributed across multiple generic manufacturers and is not generally disclosed as a separately material revenue line by those companies.
Branded revenue trajectory
Enablex was commercialized initially by Novartis and later became associated with Warner Chilcott’s commercial portfolio. Warner Chilcott was acquired by Actavis in 2013, which later became part of Allergan and then AbbVie.[5][6]
The ownership changes reduced the usefulness of historical financial comparisons. Reported company filings generally grouped Enablex with other products or disclosed it only when material. After generic entry, the brand’s revenue contribution declined sharply, while any continuing revenue depended on residual prescriptions, payer coverage, and geographic market.
Generic revenue trajectory
Generic darifenacin has a lower unit price and a more fragmented supply base. Manufacturer economics depend on:
- Annual prescription volume.
- Wholesaler and pharmacy contracts.
- Manufacturing cost per extended-release tablet.
- Active pharmaceutical ingredient sourcing.
- Number of approved competitors.
- Supply interruptions and market withdrawals.
- Reimbursement spreads.
The financial opportunity is therefore a stable, low-growth maintenance market rather than a high-value specialty franchise. A manufacturer can generate attractive returns if it has low-cost production, reliable supply, limited competition, or a differentiated geographic strategy. The product is less attractive as a stand-alone development asset for a company seeking substantial revenue growth.
How strong is the darifenacin patent estate?
The patent estate is weak from a current commercial-defense perspective because the product has already moved into generic competition.
| Patent-strength factor |
Assessment |
| Core molecule protection |
Historical value, no longer a meaningful U.S. barrier |
| Extended-release formulation |
Limited residual value after generic entry |
| Method-of-use protection |
Narrow and vulnerable to label carve-outs |
| Manufacturing patents |
Potentially relevant to individual processes, not the entire market |
| Regulatory exclusivity |
Expired |
| Generic substitution risk |
High |
| Pricing power |
Low |
| Lifecycle-management potential |
Limited without a new delivery system |
The strongest remaining intellectual property would likely be process-specific or formulation-specific. Such rights could affect one manufacturer but would not normally restore broad product exclusivity.
What paragraph IV and litigation risks exist for darifenacin?
Generic applicants historically could use Paragraph IV certifications when asserting that listed patents were invalid, unenforceable, or not infringed. A Paragraph IV notice can trigger a 30-month stay of FDA approval under the Hatch-Waxman framework if the NDA holder files an infringement action within the statutory period.[7]
For a mature product such as darifenacin, the principal litigation risks are now operational rather than strategic:
- Residual patent assertions against a specific ANDA.
- Launch-at-risk exposure during unresolved litigation.
- Product liability and labeling claims.
- Manufacturing or supply-chain disputes.
- Antitrust claims involving generic entry or settlement terms.
- Distribution and pricing investigations.
Publicly reported high-value settlement activity has not made darifenacin a major current Hatch-Waxman litigation market. The commercial importance of any historical settlement is limited by the passage of the core exclusivity period and the availability of generic products.
What generic launch scenarios exist for darifenacin?
Three launch scenarios are commercially relevant.
Scenario 1: Stable multi-source generic market
This is the base case. Several manufacturers supply the product, prices remain low, and demand tracks the broader overactive bladder market. Revenue grows mainly through prescription volume rather than price.
Scenario 2: Supply concentration
If manufacturers discontinue the product or experience manufacturing problems, a smaller number of suppliers could gain temporary share. Prices may rise, but the opportunity would depend on the duration of the shortage and the ability of other ANDA holders to restore supply.
Scenario 3: Reformulation or combination product
A new extended-release technology, combination treatment, or improved tolerability profile could create a differentiated product. This would require new clinical, formulation, or regulatory value. It would not automatically revive the original darifenacin franchise.
What is the FDA regulatory status of darifenacin?
Darifenacin remains an FDA-approved active ingredient for overactive bladder through the Enablex reference product and approved generic equivalents. The relevant regulatory pathway for new generic entrants is an ANDA demonstrating pharmaceutical equivalence and bioequivalence to the reference listed drug.[1][2]
The regulatory burden is lower than for a new chemical entity but remains meaningful for extended-release products. Applicants must address:
- Extended-release dissolution performance.
- Bioequivalence.
- Strength and dosage-form equivalence.
- Stability.
- Manufacturing controls.
- Labeling consistency.
- Product-specific pharmacokinetic requirements.
Biosimilar risk does not apply. Darifenacin is a chemically synthesized small molecule, not a biologic. Competitive risk comes from conventional generics, therapeutic substitutes, and potential reformulations.
What geographic markets remain attractive for darifenacin?
The United States is a mature generic market. Commercial opportunities are more likely to arise from supply reliability, contract manufacturing, and market access than from premium pricing.
Potentially relevant markets include:
- Europe, where generic substitution and national reimbursement decisions dominate.
- Japan, where aging demographics support overactive bladder demand but local regulatory and commercial requirements apply.
- Latin America, where branded-generic competition can produce different pricing structures.
- Emerging markets, where diagnosis and treatment rates may expand but reimbursement is less predictable.
Geographic expansion does not eliminate the product’s mature-market limitations. Local patent status, registration requirements, reference-product rules, pricing controls, and distributor economics determine actual profitability.
Key Takeaways
- Darifenacin hydrobromide is a mature M3-selective antimuscarinic for overactive bladder.
- Enablex lost its strategic commercial position after generic entry.
- The U.S. market is characterized by low pricing, multiple suppliers, and therapeutic substitution.
- The historical patent estate covered the molecule, salt, extended-release formulation, and treatment methods.
- Remaining patent value is likely narrow and product-specific rather than capable of blocking the market.
- Current standalone revenue is not publicly disclosed in a reliable, consolidated manner.
- Generic manufacturers can earn returns through manufacturing efficiency and supply reliability, not through strong pricing power.
- Biosimilar risk is irrelevant because darifenacin is a small molecule.
- The main competitive threats are solifenacin, tolterodine, oxybutynin, trospium, mirabegron, and vibegron.
- A commercially meaningful revival would require differentiated formulation, combination therapy, or a new clinical positioning.
FAQs
Is darifenacin hydrobromide still under patent protection?
The core U.S. patent protection that supported Enablex exclusivity has expired or no longer prevents generic competition. Any surviving claims would need product-specific review.
Is Enablex still sold in the United States?
Enablex is the reference brand for darifenacin extended-release tablets, but generic products have displaced it in ordinary prescribing and reimbursement channels.
Who manufactures generic darifenacin?
Generic darifenacin has been associated with multiple ANDA holders, including companies active in U.S. oral solid-dose markets such as Actavis, Apotex, and Glenmark. Supplier status changes over time.
Can darifenacin support a new branded product?
Only with meaningful differentiation. A new formulation, combination, or clinically superior tolerability profile would be needed to support premium pricing against established generics.
Does darifenacin have biosimilar competition?
No. Biosimilars apply to biologic medicines. Darifenacin faces conventional small-molecule generic competition.
References
- U.S. Food and Drug Administration. (2004). Enablex (darifenacin hydrobromide) extended-release tablets prescribing information.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Patent and Trademark Office. (2003). U.S. Patent No. 6,656,957, quinuclidine derivatives.
- American Urological Association. (2024). Diagnosis and treatment of idiopathic overactive bladder guideline.
- Warner Chilcott plc. (2012). Annual report.
- Actavis plc. (2013). Annual report and acquisition materials relating to Warner Chilcott plc.
- U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417.
